Bristol-Myers Squibb Company (BMY)

NYSE: BMY · Real-Time Price · USD
57.88
-0.35 (-0.60%)
At close: Nov 20, 2024, 4:00 PM
57.80
-0.08 (-0.14%)
Pre-market: Nov 21, 2024, 5:10 AM EST
-0.60%
Market Cap 117.39B
Revenue (ttm) 47.44B
Net Income (ttm) -7.26B
Shares Out 2.03B
EPS (ttm) -3.58
PE Ratio n/a
Forward PE 8.19
Dividend $2.40 (4.15%)
Ex-Dividend Date Oct 4, 2024
Volume 8,405,143
Open 58.61
Previous Close 58.23
Day's Range 57.67 - 58.82
52-Week Range 39.35 - 61.08
Beta 0.44
Analysts Hold
Price Target 53.92 (-6.84%)
Earnings Date Oct 31, 2024

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]

Sector Healthcare
Founded 1887
Employees 34,100
Stock Exchange NYSE
Ticker Symbol BMY
Full Company Profile

Financial Performance

In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $53.92, which is a decrease of -6.84% from the latest price.

Price Target
$53.92
(-6.84% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next ...

1 day ago - Seeking Alpha

Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.

1 day ago - Business Wire

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases

Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process f...

2 days ago - Benzinga

Bristol-Myers Squibb: Buy This Bargain Before It's Gone

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $642 mi...

3 days ago - Seeking Alpha

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite.

5 days ago - Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARE--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer.

5 days ago - Business Wire

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge ab...

6 days ago - Reuters

Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock

Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).

8 days ago - Benzinga

AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.

Other symbols: ABBV
8 days ago - Market Watch

Buy, Sell, Or Hold BMY Stock?

Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizo...

8 days ago - Forbes

Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer,...

9 days ago - Seeking Alpha

Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

9 days ago - Market Watch

AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges

On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia.

Other symbols: ABBV
9 days ago - Benzinga

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Evidence Data at AHA 2024.

9 days ago - Business Wire

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.

Other symbols: LLYNVO
12 days ago - Benzinga

What's Next For BMY Stock After An Upbeat Q3?

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings of $1.80 per sh...

14 days ago - Forbes

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Upcoming Investor Conferences.

15 days ago - Business Wire

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--BMS Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ in Adults with Schizophrenia at Psych Congress 2024.

20 days ago - Business Wire

Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript

Bristol-Myers Squibb Company (NYSE:BMY) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board...

20 days ago - Seeking Alpha

Bristol Myers's stock pops as earnings top estimates and company raises guidance

The company says it “made important strides in the third quarter.”

20 days ago - Market Watch

Bristol Myers Stock Rises After Earnings Beat, Guidance Hike

The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.

20 days ago - Barrons

Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs

Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of established drugs like blood thinner Eliquis and cancer treatment Revlimid as well as newer d...

20 days ago - Reuters

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term gro...

20 days ago - CNBC

Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2024.

20 days ago - Business Wire

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Bristol-Myers Squibb, an American multinational pharmaceutical company that discovers, develops, and markets drugs for various therapeutic areas, is now a $108 billion (by market cap) Big Pharma giant...

23 days ago - Seeking Alpha